Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliatti, Maura, Hartung, Hans-Peter, Oreja-Guevara, Celia, Pozzilli, Carlo, Airas, Laura, Alkhawajah, Mona, Grigoriadis, Nikolaos, Magyari, Melinda, Van Wijmeersch, Bart, Zakaria, Magd, Linker, Ralf, Chan, Andrew, Vermersch, Patrick, Berger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620960/
https://www.ncbi.nlm.nih.gov/pubmed/36325318
http://dx.doi.org/10.3389/fimmu.2022.1045101
Descripción
Sumario:It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Ejemplares similares